8-K: Entrada Therapeutics' ENTR-601-44 Clinical Hold Lifted by FDA, Paving Way for Phase 1b Study in Duchenne Muscular Dystrophy

The FDA has removed the clinical hold on Entrada Therapeutics' ENTR-601-44, allowing the company to proceed with a Phase 1b clinical study for Duchenne muscular dystrophy (DMD).

Summary

• Entrada Therapeutics announced that the FDA has lifted the clinical hold on ENTR-601-44.
• This allows Entrada to initiate a Phase 1b multiple ascending dose clinical study of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy (DMD) in adult patients with a confirmed mutation in the DMD gene amenable to exon 44 skipping.
• The Phase 1b study, named ELEVATE-44-102, will evaluate the safety, tolerability, and effectiveness of ENTR-601-44 in both non-ambulatory and ambulatory adult patients with DMD.
• The global ELEVATE-44 program includes the ELEVATE-44-102 study in the U.S. and ELEVATE-44-201 outside of the U.S., covering a broad population of patients with DMD.
• Entrada plans to initiate study enrollment in the first half of 2026, enabling a seamless transition into an open label extension study.
• The Phase 1b study will enroll approximately 32 patients and evaluate target engagement as measured by exon skipping and dystrophin production, and pharmacokinetics.
• Dosing will be administered every six weeks, with planned doses ranging from 0.16 mg/kg up to 1.28 mg/kg across four cohorts.

Sentiment

Score: 8

Explanation: The sentiment is positive due to the FDA lifting the clinical hold, allowing the company to advance its DMD program. The planned Phase 1b study and potential for a new treatment option contribute to the positive outlook.

Positives

• The FDA's removal of the clinical hold on ENTR-601-44 is a significant step forward for the program.
• The authorization to initiate the Phase 1b study allows Entrada to further evaluate the potential of ENTR-601-44 in treating DMD.
• The study design includes both non-ambulatory and ambulatory adult patients, addressing an unmet need in this population.
• The planned open label extension study provides an opportunity for long-term evaluation of safety and efficacy.
• The ELEVATE-44 program's global reach will allow for the evaluation of ENTR-601-44 in a broad population of DMD patients.

Risks

• The initiation of the Phase 1b study is subject to the company's ability to recruit and enroll patients.
• The results of preclinical and clinical studies may not be predictive of the results of later studies.
• The company's cash resources may not be sufficient to fund its operating expenses and capital expenditure requirements.
• Regulatory clearance may not be obtained for Investigational New Drug application applications and initiate clinical studies.

Future Outlook

Entrada plans to initiate study enrollment in the first half of 2026, which would enable a seamless transition into an open label extension study to evaluate the safety, efficacy and tolerability of ENTR-601-44 over a longer period of time.

Management Comments

• Dipal Doshi, CEO of Entrada Therapeutics, stated that the company is pleased to have obtained FDA clearance for the ELEVATE-44-102 study given the strength of safety and target engagement data and the profound unmet need in adults living with Duchenne.
• Dipal Doshi also noted that the study will help assess the potential of ENTR-601-44 in both non-ambulatory and ambulatory adult patients who are often left out of clinical studies.

Industry Context

This announcement is significant in the context of the broader DMD treatment landscape, where there is a high unmet need for effective therapies, particularly for adult patients. The development of ENTR-601-44, which targets exon 44 skipping, could provide a valuable treatment option for a specific subset of DMD patients.

Comparison to Industry Standards

• Other companies developing exon-skipping therapies for DMD include Sarepta Therapeutics, whose Exondys 51 targets exon 51 skipping.
• Entrada's ENTR-601-44 targets exon 44 skipping, addressing a different segment of the DMD population.
• The use of Entrada's Endosomal Escape Vehicle (EEV) technology aims to improve intracellular delivery and efficacy compared to traditional PMO-based therapies.

Stakeholder Impact

• Positive impact on patients with DMD who are exon 44 skipping amenable, as ENTR-601-44 could provide a new treatment option.
• Positive impact on Entrada Therapeutics' shareholders, as the advancement of the DMD program could increase the company's value.
• Potential impact on the broader DMD treatment landscape, as ENTR-601-44 could compete with existing therapies.

Next Steps

• Initiate study enrollment for the Phase 1b ELEVATE-44-102 study in the first half of 2026.
• Conduct the Phase 1b study to evaluate the safety, tolerability, and effectiveness of ENTR-601-44.
• Evaluate target engagement as measured by exon skipping and dystrophin production, and pharmacokinetics.
• Potentially transition study participants into an open label extension study.

Key Dates

Keywords

ENTR-601-44, Duchenne muscular dystrophy, DMD, FDA, Clinical hold, Phase 1b study, ELEVATE-44, Exon 44 skipping, Entrada Therapeutics